정신건강의학과 환자에서의 Liraglutide의 효과 및 안전성
Effectiveness and Safety of Liraglutide Treatment in Patients with a Psychiatric Disorder
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Objectives Liraglutide is a glucagon-like-peptide-1 receptor agonist which has been used as an anti-obesity drug. It was reported that patients might develop or worsen suicidal ideas and/or depression during liraglutide treatment, especially when it comes to patients with a psychiatric disorder. The purpose of this study was to evaluate the effectiveness and safety of liraglutide, especially in terms of the psychiatric adverse effects. Methods A retrospective chart review study was conducted on psychiatric patients prescribed liraglutide for more than one month from September 2018 to September 2020. Based on their medical records, we investigated the change in the weight and body mass index (BMI) of patients from the baseline to 6 months of receiving liraglutide treatment. Information on the adverse effects was also obtained, including psychiatric adverse effects such as insomnia, anxiety, depression, and suicidal ideation. A mixed linear model was used for assessing the time effect on change in weight and BMI. Results A total of 24 patients were included in the current study, and the most common psychiatric diagnosis included major depressive disorder (n=13, 54.2%). There was a significant change in weight (F=6.127, p=0.001) and BMI (F=6.749, p<0.001) during the liraglutide treatment. Worsening of depression and anxiety occurred in one patient but improved after the adjustment of psychiatric medications. Conclusion The current study found that liraglutide treatment in patients with a psychiatric disorder can be a safe and effective intervention for weight reduction.
Abstract
Objectives Liraglutide is a glucagon-like-peptide-1 receptor agonist which has been used as an anti-obesity drug. It was reported that patients might develop or worsen suicidal ideas and/or depression during liraglutide treatment, especially when it comes to patients with a psychiatric disorder. The purpose of this study was to evaluate the effectiveness and safety of liraglutide, especially in terms of the psychiatric adverse effects. Methods A retrospective chart review study was conducted on psychiatric patients prescribed liraglutide for more than one month from September 2018 to September 2020. Based on their medical records, we investigated the change in the weight and body mass index (BMI) of patients from the baseline to 6 months of receiving liraglutide treatment. Information on the adverse effects was also obtained, including psychiatric adverse effects such as insomnia, anxiety, depression, and suicidal ideation. A mixed linear model was used for assessing the time effect on change in weight and BMI. Results A total of 24 patients were included in the current study, and the most common psychiatric diagnosis included major depressive disorder (n=13, 54.2%). There was a significant change in weight (F=6.127, p=0.001) and BMI (F=6.749, p<0.001) during the liraglutide treatment. Worsening of depression and anxiety occurred in one patient but improved after the adjustment of psychiatric medications. Conclusion The current study found that liraglutide treatment in patients with a psychiatric disorder can be a safe and effective intervention for weight reduction.
참고문헌 (32)
- Chang CK, "Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London", PLoS One, 6, pp.e19590~ (2011)
- Popovic D, "Risk factors for suicide in schizophrenia : systematic review and clinical recommendations", Acta Psychiatr Scand, 130, pp.418~426 (2014)
- Chacón F, "Efficacy of lifestyle interventions in physical health management of patients with severe mental illness", Ann Gen Psychiatry, 10, pp.22~ (2011)
- Hoang U, "Avoidable mortality in people with schizophrenia or bipolar disorder in England", Acta Psychiatr Scand, 127, pp.195~201 (2013)
- Walker ER, "Mortality in mental disorders and global disease burden implications : a systematic review and meta-analysis", JAMA Psychiatry, 72, pp.334~341 (2015)
- Mayor S, "Patients with severe mental illness have greatly increased cardiovascular risk, study finds", BMJ, 357, pp.j2339~ (2017)
- Holt RI, "Obesity, serious mental illness and antipsychotic drugs", Diabetes Obes Metab, 11, pp.665~679 (2009)
- Jensen MD, "2013 AHA", ACC, American Heart Association Task Force on Practice Guidelines and The Obesity Society, pp.Circulation, 2014[DOI]
- Naslund JA, "Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness : a systematic review and meta-analysis", Gen Hosp Psychiatry, 47, pp.83~102 (2017)
- Whicher CA, "Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial", Trials, 20, pp.633~ (2019)
- Larsen JR, "Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-or olanzapine-treated patients with schizophrenia spectrum disorder : a randomized clinical trial", JAMA Psychiatry, 74, pp.719~728 (2017)
- 강준구, "Anti-Obesity Drugs: A Review about Their Effects and Safety", Diabetes and Metabolism Journal, 36(1), pp.13~25 (2012), 대한당뇨병학회
- "Draft guidance for industry on diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention"[URL]
- Rodgers RJ, "Anti-obesity drugs: past, present and future", Dis Model Mech, 5, pp.621~626 (2012)
- Nathan PJ, "Neuropsychiatric adverse effects of centrally acting antiobesity drugs", CNS Neurosci Ther, 17, pp.490~505 (2011)
- Aronne LJ, "A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a highdose study", Int J Obes (Lond), 34, pp.919~935 (2010)
- Cuomo A, "Feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity", Front Psychiatry, 9, pp.784~ (2019)
- Knudsen LB, "Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin", cocaine-and amphetamine-stimulated transcript neurons in the mouse hypothalamus, 2016, pp.7, 56~63
- van Can J, "Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults", Int J Obes(Lond), 38, pp.784~793 (2014)
- O’Neil PM, "Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials", Diabetes Obes Metab, 19, pp.1529~1536 (2017)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychaitric Association
- "The R Project for statistical computing"[URL]
- Hansen AH, "Gender differences in the use of psychiatric outpatient specialist services in Tromsø, Norway are dependent on age: a population-based cross-sectional survey", BMC Health Serv Res, 15, pp.477~ (2015)
- McLean CP, "Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness", J Psychiatr Res, 45, pp.1027~1035 (2011)
- Schuch JJ, "Gender differences in major depressive disorder : results from the Netherlands study of depression and anxiety", J Affect Disord, 156, pp.156~163 (2014)
- Patterson L, "The relationship between BMI and the prescription of anti-obesity medication according to social factors : a population cross sectional study", BMC Public Health, 14, pp.87~ (2014)
- Matthiasdottir E, "Body weight dissatisfaction in the Icelandic adult population : a normative discontent", Eur J Public Health, 22, pp.116~121 (2012)
- Mojtabai R, "National trends in psychotropic medication polypharmacy in office-based psychiatry", Arch Gen Psychiatry, 67, pp.26~36 (2010)
- Sarkar S, "Psychiatric polypharmacy, etiology and potential consequences", Curr Psychopharmacol, 6, pp.12~26 (2017)
- Lim JU, "Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients", Int J Chron Obstruct Pulmon Dis, 12, pp.2465~2475 (2017)
- Weisell RC, "Body mass index as an indicator of obesity", Asia Pacific J Clin Nutr, 11, pp.S681~S684 (2002)